Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.

Biotechnology

Foghorn Therapeutics

Foghorn Therapeutics' headquarters in Cambridge, MA, United States

Adrian Gottschalk

Steven Bellon

Jeff Sacher

Sunita Katyal

Kristian F. Humer

Anna Rivkin

Alfonso Quintás-Cardama

Karin Hellsvik

Michael Lacascia

Carlos Costa

Scott Biller

Michael Mendelsohn

Tony Kouzarides

Adam Koppel

David Schenkein

Ian Smith

Charles L. Sawyers

Gerald Crabtree

Simba Gill

Doug Cole

Cigall Kadoch

Lynne Parshall

Tom Lynch

The Directors and Advisors team at Foghorn Therapeutics provides strategic guidance and expert oversight for the company's pioneering efforts in drug discovery and development within the chromatin regulatory system. They leverage their extensive experience to drive the identification and validation of potential drug targets, ensuring the company's proprietary Gene Traffic Control platform is effectively utilized to advance promising therapeutic candidates.

Directors and Advisors

The Leadership Team at Foghorn Therapeutics is responsible for setting the strategic direction and overseeing the company's initiatives in discovering and developing innovative therapies targeting the chromatin regulatory system. This team, composed of executives across various functions such as scientific research, investor relations, legal affairs, and human resources, collaborates to ensure the successful advancement of drug candidates, guide corporate communications, foster a strong company culture, and maintain compliance with regulatory standards. Their collective expertise drives the mission to unlock new treatment opportunities for patients by leveraging the Gene Traffic Control platform.

Leadership Team

The Vice Presidents at Foghorn Therapeutics are responsible for leading their respective departments and driving the company's strategic initiatives. They oversee crucial areas such as investor relations, drug discovery, chemistry, biology, corporate affairs, and information technology. Together, they ensure cohesive execution of the company's mission to develop innovative medicines targeting the chromatin regulatory system by leveraging the Gene Traffic Control platform.

Vice Presidents

��

Foghorn Therapeutics

Org chart

Board & advisors

Teams

Directors and Advisors

Leadership Team

Vice Presidents

Offices

��������

Foghorn Therapeutics

Org chart

Board & advisors

Teams

Directors and Advisors

Leadership Team

Vice Presidents

Offices

Related companies

��